Edesa Biotech, Inc. — Director's Dealing 2014

Nov 14, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stellar Biotechnologies, Inc. (SBOTF)
CIK: 0001540159
Period of Report: 2014-11-12

Reporting Person: NIFFENEGGER KATHI (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-11-12	Stock Option (Right To Buy)	$1.3439	A	90000	Acquired	2021-11-12	Common Shares (90000)	Direct

Footnotes

F1: The options are exercisable at a price of C$1.52. The U.S. dollar price reported on this Form 4 in column 2 reflects the U.S. dollar equivalent exercise price on the date of grant, calculated at the closing price for cable transfers in Canadian dollars as reported by Bloomberg on such date of U.S.$1.00 = CDN$1.1311.

F2: One-third of the option vested immediately, one-third of the option vests on the first anniversary of November 12, 2014, and one-third of the option vests 18 months after November 12, 2014.